first drug approved for early Alzheimer’s disease in the UK
On Aug. 22, 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) announced it had licensed the immunotherapy…
-
-
Accuracy of diagnostic blood tests for Alzheimer’s disease varies
On Jul. 30, 2024, a head-to-head comparison of six commercially available blood tests for Alzheimer’s disease led by…
-
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
In Jul. 10, 2024, Eisai and Biogen announced that the Department of Health in Hong Kong has approved…
-
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
On Jun. 27, 2024, C2N Diagnostics (C2N), has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for…
-
Biotechnology | Diagnostics | Disease | Imaging | Medical Device | Nanotechnology | Neurology | Non-Profit Research | Therapeutics
Imaging technique shows new details of peptide structures
On Apr. 26, 2024, engineers at Washington University in St. Louis announced a new imaging technique that give…
-
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
-
‘LEQEMBI’ (Lecanemab) approved for treatment of Alzheimer’s disease in China
On Jan. 9, 2024, Biogen and Eisai announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody ‘LEQEMBI’…
-
Diagnostics | Disease | Medical Device | NIH | Oncology | Therapeutics | U.S. Congress
ARPA-H launched program for real-time drug delivery and disease tracking to improve patient self-care
On Sept. 26, 2023, the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA granted traditional approval for LEQEMBI (lecanemab-irmb) for the treatment of Alzheimer’s disease
On Jul. 6, 2023, Eisai and Biogen announced that the U.S. Food and Drug Administration (FDA) had approved the…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA approved first drug to treat agitation symptoms associated with dementia due to Alzheimer’s disease
On May 11, 2023, the U.S. Food and Drug Administration (FDA) announced the supplemental approval of Otsuka Pharmaceutical…
-
A 19-Year-Old Adolescent with Probable Alzheimer’s Disease
On Jan. 31, 2023, a team of researchers led by the Innovation Center for Neurological Disorders and Department…
-
Cell by cell, scientists building a high-resolution map of brain changes in Alzheimer’s disease
On Jul. 28, 2022, the Allen Institute announced a newly released dataset of 1.2M cells from brain donors…
-
Stanford University launched $75 million brain disease initiative
On Apr. 26, 2022, Stanford University announced it was awarded a $75 million gift from Nike co-founder Phil…
-
Blood test for Alzheimer’s highly accurate in large, international study
On Feb. 22, 2022, Washington University in St. Louis announced that a blood test developed at the University’s…
-
Clinical Research | Disease | Neurology | NIH | Therapeutics
NIH unveiled new online tool to improve Alzheimer’s clinical trials recruitment
On Jul. 29, 2021, the National Institutes of Health (NIH) announced it had launched a new online research…
-
Disease | FDA | Neurology | Therapeutics
Eisai and Biogen announced FDA granted Breakthrough Therapy Designation for Lecanemab for treatment of Alzheimer’s disease
On Jun. 23, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
Biotechnology | Disease | FDA | Neurology | Therapeutics
FDA granted accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment
On Jun. 7, 2021, Biogen and Eisai announced that the U.S. Food and Drug Administration (FDA) had granted…
-
McGill University researchers led by Bratislav Misic announced a direct link between gene expression and higher brain function
On Mar. 25, 2021, McGill University researchers led by Bratislav Misic announced a direct link between gene expression…
-
Biotechnology | Disease | Neurology | NIH | Therapeutics
NIH invested in next iteration of public-private partnership to advance precision medicine for Alzheimer’s disease
On Mar. 2, 2021, the National Institutes of Health (NIH) announced it had launched the next version of…
-
Racial differences in Alzheimer’s research focus of $15 million grant
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
-
NIH awarded $13.8 million for studies on the prevention and treatment of Alzheimer’s disease
On Oct. 5, 2020, Joe Verghese, M.B.B.S., M.S., an international leader in aging and cognition research at Albert…
-
Biotechnology | Disease | Neurology | NIH | Therapeutics
NIH augmented large scale study of Alzheimer’s disease biomarkers
On Sept. 14, 2020, the National Institutes of Health (NIH) announced that it had added funding for more…
-
Biotechnology | Diagnostics | Disease | Neurology | NIH | Stem Cell | Therapeutics
Albert Einstein College of Medicine received $16 million NIH grant to study cellular process linked to Alzheimer’s disease
On Sept. 8, 2020, researchers at Albert Einstein College of Medicine, led by Ana Maria Cuervo, M.D., Ph.D.,…
-
Biotechnology | Diagnostics | Disease | Neurology | NIH | Therapeutics
Seattle researchers teamed up to build hi-res brain map of Alzheimer’s disease
On Jun. 25, 2020, the Allen Institute announced a new a new $40.5 million collaborative research center in…
-
Biotechnology | Diagnostics | Disease | Neurology | NIH | Therapeutics
OHSU received more than $11 million to continue brain, cognitive development research
On Apr. 17, 2020, the National Institutes of Health (NIH) announced nearly $290 million of new funding for…
-
Alzheimer’s trial screening data links high amyloid levels with early stage disease
On Apr. 6, 2020, the first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study…
-
Research on brain structure highlighted cells linked to Alzheimer’s and autism
On Mar. 16, 2020, new insights into the architecture of the brain were revealed by scientists at the…
-
Dr. Pedro Rosa-Neto announced the discovery that the protein APOEﾠꜫ4 ﾠplays a central role in Alzheimer’s disease
On Dec. 20, 2019, Dr. Pedro Rosa-Neto announced the discovery that the protein APOEꜫ4 plays a central role…
-
Emory Selected to lead international drug discovery center for Alzheimer’s
On Oct 1, 2019, the National Institute on Aging (NIA) announced it had awarded approximately $37 million over…
-
UPenn’s Center for Neurodegenerative Disease Research received an $18.1 million grant from NIH
On Sept. 30, 2019, UPenn’s Center for Neurodegenerative Disease Research (CNDR) announced it had received a grant expected…
